Portaccio, Emilio published the artcileImpact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey, Safety of Dimethyl fumarate, the publication is Multiple Sclerosis Journal (2022), 28(1), 132-138, database is CAplus and MEDLINE.
Background:: The spread of Coronavirus disease-19 (COVID-19) poses unique challenges in the management of people with multiple sclerosis (PwMS). Objectives:: To collect data about the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices. Methods:: Between March and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) promoted an online survey covering patient access to care, management of relapses and visits, disease-modifying therapy (DMT) and experience with COVID-19. Results:: Three-hundred and sixty neurologists from 52 countries (68from Europe) completed the survey. 98reported COVID-19-related restrictions. Telemedicine was adopted to overcome the limited access to care and was newly activated (73) or widely implemented (17). 70reported changes in DMT management. Interferons and glatiramer were considered safe. No modifications were considered for natalizumab in 64, cladribine in 24, anti-CD20 in 22and alemtuzumab in 17; 18(for alemtuzumab and cladribine) and 43(for anti-CD20) considered postponing treatment. Conclusion:: The ECTRIMS survey highlighted the challenges in keeping standards of care in clin. practice. Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions.
Multiple Sclerosis Journal published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C6H8O4, Safety of Dimethyl fumarate.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics